Table of Contents
<< Previous Issue | May 2014 (Vol: 2014, Issue: 5) | Next Issue >> |
- Section: Licensing
-
Celgene Pays US$710 M Upfront to License Nogra Pharma’s Phase III-Ready GED-0301
-
Roche Partners with Oryzon Genomics and Spero Therapeutics
- Section: Mergers & Acquisitions
-
Baxter Strengthens Haemophilia Franchise with Chatham Therapeutics Purchase as Biogen Enters Market
-
Sun Pharma Agrees to Buy Struggling Ranbaxy from Daiichi Sankyo in US$4 B Deal
-
Mallinckrodt Expands Speciality Pharmaceuticals Business with US$5.6 B Questcor Acquisition
-
Novartis and GSK Shift M&A Paradigm with Trio of Deals
-
BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets
-
Forest Expands Gastrointestinal Portfolio with up to US$1.46 B Furiex Purchase
-
BMS Buys iPierian and its Anti-Tau Programme for a Potential US$725 M
-
Bayer Wins Auction for Merck & Co.’s OTC Business and Offers Cardiovascular Disease Collaboration Sweetener